MedTrace Logo

Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder

NCT00834834 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2017-08-18

Study results available
· View outcomes & findings →

Summary

This study will compare the effectiveness of two treatments, dialectical behavior therapy versus fluoxetine with clinical management, for reducing the risk of self-injury and suicidal behavior in people with borderline personality disorder.

Conditions

  • Borderline Personality Disorder
  • Suicide

Interventions

DRUG

Fluoxetine

Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.

BEHAVIORAL

DBT

One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.

DRUG

Citalopram

Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Barbara H. Stanley, PhD · New York State Psychiatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00834834 on ClinicalTrials.gov